IPO Profile: Nivalis Therapeutics Inc

The company, which develops drugs to treat cystic fibrosis, raised $77 million in its IPO

1 July 2015•1 min read

[data-article-body-skeleton]{display:none!important}

JavaScript is required to read this article. Please enable it in your browser and reload the page.